Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset - HMS LINCS Database

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)

Download: Excel (XLSX), Comma-separated (CSV)

Filter results: >>>>

|<
<<
Previous
Page 14 of 18
Next
>>
>
326 to 350 of 432 records
per page:

Cell line	Drug name	Experimental replicate	Timepoint	Curve type (GR values)	Curve type (relative cell counts)	Experiment name	Number of concentrations	Cell doublings (DMSO control)	GR50	GRmax	GR_AOC	GEC50	GRinf	Hill slope (GR values)	R-squared sigmoid fit (GR values)	P-value sigmoid fit (GR values)	R-squared flat fit (GR values)	IC50	Emax	AUC	EC50	Einf	Hill slope (relative cell counts)	R-squared sigmoid fit (relative cell counts)	P-value sigmoid fit (relative cell counts)	R-squared flat fit (relative cell counts)
HCC1806	KIN001-244	2	72	flat	flat	HCC1806 KIN001-244 0 2 72	8	2.827	Inf	0.986	0.0229	0.0	0.986	0.01	-0.0574	1.0	0.98	Inf	0.981	0.968	0.0	0.981	0.01	-0.0553	1.0	0.972
HCC1806	KIN001-244	3	72	flat	flat	HCC1806 KIN001-244 0 3 72	8	3.195	Inf	0.988	0.0203	0.0	0.988	0.01	-0.0575	1.0	0.982	Inf	0.981	0.968	0.0	0.981	0.01	-0.0553	1.0	0.972
HCC1806	MK2206	1	72	sigmoid	sigmoid	HCC1806 MK-2206 0 1 72	8	2.746	47.7	0.818	0.0504	320.0	-0.715	0.466	0.981	7.02e-06	NA	Inf	0.769	0.934	4.46	0.507	0.566	0.976	1.46e-05	NA
HCC1806	MK2206	2	72	sigmoid	sigmoid	HCC1806 MK-2206 0 2 72	8	2.831	51.9	0.823	0.0489	320.0	-0.668	0.467	0.981	7.01e-06	NA	Inf	0.769	0.934	4.46	0.507	0.566	0.976	1.45e-05	NA
HCC1806	MK2206	3	72	sigmoid	sigmoid	HCC1806 MK-2206 0 3 72	8	3.199	74.1	0.843	0.0434	320.0	-0.491	0.468	0.981	6.96e-06	NA	Inf	0.769	0.934	4.46	0.507	0.566	0.976	1.46e-05	NA
HCC1806	PI103	1	72	sigmoid	sigmoid	HCC1806 PI-103 0 1 72	8	2.673	Inf	0.895	0.00682	1.71	0.853	1.43	0.781	0.0106	NA	Inf	0.866	0.992	1.61	0.817	1.44	0.762	0.0134	NA
HCC1806	PI103	2	72	sigmoid	sigmoid	HCC1806 PI-103 0 2 72	8	2.758	Inf	0.898	0.00662	1.71	0.857	1.43	0.781	0.0105	NA	Inf	0.866	0.992	1.61	0.817	1.44	0.762	0.0134	NA
HCC1806	PI103	3	72	sigmoid	sigmoid	HCC1806 PI-103 0 3 72	8	3.126	Inf	0.91	0.00588	1.72	0.873	1.43	0.782	0.0103	NA	Inf	0.866	0.992	1.61	0.817	1.44	0.762	0.0134	NA
HCC1806	PIK-93	1	72	sigmoid	sigmoid	HCC1806 PIK-93 0 1 72	8	2.753	44.0	0.853	0.0391	304.0	-1.0	0.568	0.858	0.00285	NA	46.6	0.811	0.948	46.6	0.0	0.57	0.84	0.00406	NA
HCC1806	PIK-93	2	72	sigmoid	sigmoid	HCC1806 PIK-93 0 2 72	8	2.838	41.1	0.857	0.038	265.0	-1.0	0.59	0.858	0.00286	NA	46.6	0.811	0.948	46.6	0.0	0.57	0.84	0.00406	NA
HCC1806	PIK-93	3	72	sigmoid	sigmoid	HCC1806 PIK-93 0 3 72	8	3.206	56.0	0.873	0.0337	320.0	-0.872	0.579	0.859	0.00279	NA	46.6	0.811	0.948	46.6	0.0	0.57	0.84	0.00406	NA
HCC1806	Sirolimus	1	72	sigmoid	sigmoid	HCC1806 rapamycin 0 1 72	8	2.796	1.35	0.775	0.187	0.00019	0.706	0.1	0.661	0.039	NA	1.05	0.717	0.76	1e-05	0.657	0.1	0.68	0.0328	NA
HCC1806	Sirolimus	2	72	sigmoid	sigmoid	HCC1806 rapamycin 0 2 72	8	2.881	0.901	0.782	0.182	0.000189	0.714	0.1	0.661	0.0388	NA	149.0	0.717	0.76	0.000153	0.626	0.1	0.634	0.0489	NA
HCC1806	Sirolimus	3	72	sigmoid	sigmoid	HCC1806 rapamycin 0 3 72	8	3.249	0.223	0.805	0.162	0.000183	0.746	0.1	0.663	0.0382	NA	1.05	0.717	0.76	1e-05	0.657	0.1	0.68	0.0328	NA
HCC1806	TGX221	1	72	flat	flat	HCC1806 TGX-221 0 1 72	8	2.679	Inf	1.0	-0.0118	0.0	1.0	0.01	-1.16	1.0	1.01	Inf	1.0	1.02	0.0	1.0	0.01	-1.16	1.0	1.02
HCC1806	TGX221	2	72	flat	flat	HCC1806 TGX-221 0 2 72	8	2.763	Inf	1.0	-0.0114	0.0	1.0	0.01	-1.16	1.0	1.01	Inf	1.0	1.02	0.0	1.0	0.01	-1.16	1.0	1.02
HCC1806	TGX221	3	72	flat	flat	HCC1806 TGX-221 0 3 72	8	3.132	Inf	1.0	-0.0101	0.0	1.0	0.01	-1.16	1.0	1.01	Inf	1.0	1.02	0.0	1.0	0.01	-1.16	1.0	1.02
HCC1806	Torin1	1	72	sigmoid	sigmoid	HCC1806 Torin1 0 1 72	8	2.755	0.303	0.246	0.317	0.152	0.185	0.669	0.988	1.74e-06	NA	0.186	0.272	0.651	0.0697	0.26	0.75	0.992	4.55e-07	NA
HCC1806	Torin1	2	72	sigmoid	sigmoid	HCC1806 Torin1 0 2 72	8	2.840	0.336	0.264	0.309	0.154	0.203	0.668	0.988	1.77e-06	NA	0.186	0.272	0.651	0.0697	0.26	0.75	0.992	4.55e-07	NA
HCC1806	Torin1	3	72	sigmoid	sigmoid	HCC1806 Torin1 0 3 72	8	3.208	0.537	0.332	0.278	0.165	0.271	0.662	0.988	1.91e-06	NA	0.186	0.272	0.651	0.0697	0.26	0.75	0.992	4.55e-07	NA
HCC1806	Torin2	1	72	sigmoid	sigmoid	HCC1806 Torin2 0 1 72	8	2.759	0.0569	-0.203	0.582	0.0763	-0.234	1.3	0.996	6.76e-08	NA	0.0486	0.079	0.492	0.0442	0.0528	1.17	0.995	1.09e-07	NA
HCC1806	Torin2	2	72	sigmoid	sigmoid	HCC1806 Torin2 0 2 72	8	2.843	0.0589	-0.181	0.57	0.0771	-0.211	1.3	0.996	6.72e-08	NA	0.0486	0.079	0.492	0.0442	0.0528	1.17	0.995	1.08e-07	NA
HCC1806	Torin2	3	72	sigmoid	sigmoid	HCC1806 Torin2 0 3 72	8	3.212	0.0678	-0.0927	0.522	0.0798	-0.12	1.32	0.996	6.56e-08	NA	0.0486	0.079	0.492	0.0442	0.0528	1.17	0.995	1.09e-07	NA
HCC1806	Trametinib	1	72	sigmoid	sigmoid	HCC1806 trametinib 0 1 72	8	2.751	Inf	0.795	0.139	0.00972	0.802	0.873	0.97	2.67e-05	NA	Inf	0.742	0.822	0.00864	0.752	0.892	0.97	2.67e-05	NA
HCC1806	Trametinib	2	72	sigmoid	sigmoid	HCC1806 trametinib 0 2 72	8	2.836	Inf	0.8	0.135	0.00973	0.808	0.873	0.97	2.67e-05	NA	Inf	0.742	0.822	0.00864	0.752	0.892	0.97	2.67e-05	NA

|<
<<
Previous
Page 14 of 18
Next
>>
>
326 to 350 of 432 records
per page:

HMS LINCS Project

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)